Stride, Inc. LRN continues to deliver robust margin growth. In third-quarter fiscal 2025, the company reported a robust performance with adjusted EBITDA rising 40% year over year to a record $168.3 ...
RingCentral maintains a BUY rating despite a target price reduction from $72 to $67, reflecting recalibrated valuation multiples. RNG's profitability is accelerating, with EBITDA forecast for 2025 ...
Innodata Inc. INOD delivered another standout quarter in the second quarter of 2025, with results underscoring its strong operating leverage and expanding role in the AI services ecosystem. Revenues ...
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback